
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc. is poised for a strong financial performance, with annual Korlym sales projected to grow by 19% to 26% year-over-year, reflecting robust underlying demand and a significant increase in volume over the past two quarters. The potential expansion of relacorilant into additional cancer indications, bolstered by promising clinical trial results, indicates a substantial growth trajectory for the company's product pipeline. Furthermore, the anticipated growth of the Cushing’s syndrome market and the capacity improvement over time could contribute to the franchise evolving into a multi-billion dollar market segment within the next five years.
Bears say
Corcept Therapeutics is facing potential near-term earnings headwinds, particularly with expected downward revisions to its 2025 revenue guidance, which is projected to fall to $824 million, below the current guidance range of $850 million to $900 million. The company has lowered its sales forecast for Korlym by approximately 10% for the latter half of 2025, reflecting ongoing challenges related to commercial distribution and supply chain issues. Furthermore, the departure of Optime might indicate underlying instability within the management strategy, contributing to a cautious outlook on the company's financial performance moving forward.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares